There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
| Orders | Qty | Bid |
|---|---|---|
| 4 | 1339 | 959.65 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| Ask | Qty | Orders |
|---|---|---|
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
Annual Revenue,rose 10.79%, in the last year to ₹5,613.89 Cr. Its sector's average revenue growth for the last fiscal year was 10.62%.Annual Net Profit,rose 123.18% in the last year to ₹358.32 Cr. Its sector's average net profit growth for the last fiscal year was 36.73%.Quarterly Revenue,rose 35.12% YoY to ₹1,680.43 Cr. Its sector's average revenue growth YoY for the quarter was 9.61%.
Laurus Labs Limited is a research-driven, integrated pharmaceutical company engaged across Contract Development and Manufacturing (CDMO), Generics Finished Dosage Forms (FDF), Active Pharmaceutical Ingredients (APIs), and Biotechnology. Its offerings span development to large-scale manufacturing for pharma, biotech, animal health, crop science and specialty ingredients, supported by state-of-the-art R&D and compliant manufacturing facilities. The company serves a global customer base with products distributed in 80+ countries, with 68 Per cent of revenue from exports and a regional mix of 20 Per cent North America, 25 Per cent Europe and 55 Per cent Rest of World . As on the reporting date, Laurus Labs has 8 subsidiaries (including step-down subsidiaries) .
Key milestones and profile highlights:
– Established expertise in complex chemistry and advanced manufacturing, including India’s large Hi-Potent API capabilities and leadership in antiretroviral APIs .
– A diversified portfolio now includes integrated API/FDF development and microbial precision fermentation through its biotech arm .
– 15 development and manufacturing sites and five R&D centres supporting global supply and innovation pipelines .
– Trusted by 250+ global customers, with products distributed in 80+ countries .
– Revenue contribution by division (FY25): Generics (API and FDF) 72 Per cent; CDMO 25 Per cent; Biotechnology 3 Per cent .
– Revenue contribution by geography: 68 Per cent exports; 32 Per cent domestic. Regional mix: 20 Per cent North America, 25 Per cent Europe and 55 Per cent Rest of World .
– Dr. K. Ravindranath – Non-Executive Chairman and Independent Director .
– Dr. Satyanarayana Chava – Executive Director & Chief Executive Officer .
– Mr. V. V. Ravi Kumar – Executive Director & Chief Financial Officer .
– Dr. C. V. Lakshmana Rao – Executive Director – Quality .
– Mr. Krishna Chaitanya Chava – Executive Director – Synthesis .
– Ms. Soumya Chava – Executive Director – Generics .
– G. Venkateswar Reddy – Company Secretary & Compliance Officer .
– Opened a 200,000 sq. ft. small-molecule R&D centre at IKP Knowledge Park, Telangana in September 2024, established with an initial investment of Rs 250 crore, and expected to create employment for over 800 professionals in two years .
– Laurus Bio secured an equity investment of Rs 120 crore from Eight Roads Ventures and F-Prime Capital, with Laurus Labs co-investing Rs 40 crore in December 2024 to expand microbial fermentation capabilities for bio-based proteins and enzymes .
– Formed a joint venture, KRKA Pharma Private Limited, with a 49 Per cent stake; investment of Rs 105.35 crore, accounted as a joint venture with effect from October 03, 2024 .
– Commissioned a new Drug Substance block at Unit-4; Animal Health DS facility (LSLP-U2) made operational (MB-3), with MB-4 under construction; Agrochemicals facility at LSPL Unit-4 brought online .
– Received Establishment Inspection Reports for the Unit 4 API facility and completed 160+ quality audits in FY25 with no critical findings .
– Recognitions: 2024 DET Hurun Award; named among India’s top 75 innovative companies by CII; Export Performance Award at IPHEX; multiple safety and manufacturing excellence awards for Units 1–3 .
Laurus Labs operates across CDMO, Generics (APIs and FDF), and Biotechnology, offering integrated research, development and manufacturing solutions globally . Its expertise spans complex chemistry, oral solids and microbial precision fermentation .
Laurus Labs’ products are distributed in 80+ countries, with 68 Per cent of revenue from exports and a regional mix of 20 Per cent North America, 25 Per cent Europe and 55 Per cent Rest of World . The company serves 250+ global customers .
Key developments included the new 200,000 sq. ft. R&D centre in Telangana, a strategic investment round in Laurus Bio, and the formation of a 49 Per cent JV in KRKA Pharma Private Limited . The company also commissioned new manufacturing capacities and received quality recognitions and regulatory confirmations .
